Purchase this article with an account.
DA SapersteinVOH Study Group; Effects Over Two Years of Verteporfin Therapy on Choroidal Neovascularization Secondary to the Ocular Histoplasmosis Syndrome (VOH Study) . Invest. Ophthalmol. Vis. Sci. 2002;43(13):982.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To present the 2-year results of the Verteporfin in Ocular Histoplasmosis Syndrome (VOH) Study, which was an open-label, uncontrolled study investigating the safety and effects on visual acuity of verteporfin (Visudyne®, Novartis AG) therapy in patients with subfoveal choroidal neovascularization (CNV) due to the ocular histoplasmosis syndrome (OHS). Methods: At the initial visit, all patients received verteporfin therapy as in the TAP Investigation, and were retreated at 3-monthly follow-up visits if fluorescein leakage from CNV was seen on angiography. Vision outcomes were assessed based on change in visual acuity and contrast sensitivity, and the proportion of patients gaining 7 or more letters, losing at least 8 letters, or losing at least 15 letters of visual acuity. Results: Twenty-five patients with a best-corrected visual acuity letter score of 73-34 (Snellen equivalent approximately 20/40 to 20/200) were enrolled at three centers. Twenty-two (88%) continued to the month 24 examination, at which time 10 (45%) patients gained 7 or more letters (1.4 lines) of visual acuity from baseline. Four (18%) patients lost at least 8 letters (1.6 lines), of which two (9%) lost at least 15 letters (3 lines). Median visual acuity letter score increased by 6.0 letters from baseline. Contrast sensitivity increased by 3 or more letters (at least 0.3 log unit) in 16 patients (73%), and decreased by 3 or more letters in one patient (5%). No treatment-related serious adverse events were reported. Conclusion: These results support the month 12 findings that verteporfin therapy is safe and may be effective for the treatment of subfoveal CNV secondary to OHS.
This PDF is available to Subscribers Only